Edwyn
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | $24,689 | $27,305 | $27,281 | $27,116 | $28,754 |
| Gross Profit | $5,930 | $20,704 | $21,624 | $20,618 | $22,503 |
| Operating Income | $4,071 | $9,918 | $7,330 | $7,605 | $1,662 |
| Net Income | $123 | $6,225 | $4,592 | $5,665 | $480 |
Over the five-year period, Gilead Sciences’ revenue shows modest growth overall—from USD 24,689 million in 2020 to USD 28,754 million in 2024—after an initial jump of about 10.7% from 2020 to 2021. Gross profit underwent a significant improvement, rising from USD 5,930 million in 2020 to over USD 20,700 million in 2021, and remaining relatively stable thereafter. This strong gross margin performance indicates robust pricing strategies or cost efficiencies in production and research. However, a closer look at operating income and net income reveals notable volatility. Operating income peaked at USD 9,918 million in 2021, then experienced a decline in subsequent years—with a dramatic drop to USD 1,662 million in 2024, representing a decline of nearly 78% from the 2023 level. Net income follows a similar trend, where the leap from a mere USD 123 million in 2020 to USD 6,225 million in 2021 is contrasted by substantial declines to USD 480 million in 2024. This pronounced contraction in operating and net earnings in 2024, exceeding a 20% drop year-over-year, signals potential operational challenges or shifts in expense structure during that period. Given Gilead Sciences’ prominent position in the pharmaceutical and biotechnology arena—where R&D investment intensity and regulatory dynamics are strong cost drivers such swings—the downturn might be driven by increased R&D spending, higher operational risks, or market pricing pressures. Overall, while the company demonstrates solid revenue and gross profit trends, the significant declines in operating and net income in the later period warrant closer examination to ensure sustainable margin management and financial health moving forward.
This analysis is for informational purposes only and does not constitute financial advice or recommendations for any investment decisions. Please consult with a qualified financial professional for personalized guidance.